A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation
Jing Xu, Zhong‐Yang Shen, Xin‐Guo Chen, Qing Zhang, Hui‐Jie Bian, Ping Zhu, Hui‐Yun Xu, Fei Song, Xiang‐Min Yang, Li Mi, Qing‐Chuan Zhao, Rong Tian, Qiang Feng, Si‐He Zhang, Yu Li, Jian‐Li Jiang, Ling Li, Xiao‐Ling Yu, Zheng Zhang, Zhi‐Nan Chen – 26 January 2007 – Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria.